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Heat shock protein 90 (hsp90) regulates stability and
function of many client proteins including members of
the NO-cGMP signaling pathway. Soluble guanylyl
cyclase (sGC), which is the main intracellular receptor of
NO, was recently reported to be an hsp90 interacting part-
ner. In the present study, we show that hsp90 binds to
both subunits of the most common sGC form, α1β1. Char-
acterization of the region of hsp90 required to bind each
subunit in immunoprecipitation experiments, revealed
that residues 310-456 of hsp90 interact with both α1 andβ1. The region of β1 responsible for binding to hsp90β was
mapped using in vitro binding assays and immunoprecip-
itation experiments and found to lie in the regulatory
domain. The physiological importance of the hsp90/sGC
interaction was investigated by treating rat smooth muscle
cells (RASMC) with the hsp90 inhibitors radicicol (RAD)
and geldanamycin (GA) and determining both sGC activ-
ity and protein levels. Long-term (24 or 48 hr) inhibition
of hsp90 resulted in a strong decrease of both α1 and β1
protein levels, as well as sGC activity. Moreover, incuba-
tion of smooth muscle cells with the proteasome inhibitor
MG132 blocked the GA-induced downregulation of sGC.
We conclude that the α1 and β1 sGC interact with the M
domain of hsp90 and that this interaction regulates the
pool of active sGC by affecting the protein levels of the
two subunits.
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